Liquidia (NASDAQ:LQDA) Price Target Raised to $65.00

Liquidia (NASDAQ:LQDA) had its target price lifted by HC Wainwright from $58.00 to $65.00 in a research note released on Thursday, Marketbeat reports. They currently have a buy rating on the stock.

Several other research firms have also issued reports on LQDA. Wells Fargo & Company lifted their price target on shares of Liquidia from $30.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Wedbush set a $58.00 price target on Liquidia in a report on Friday, October 2nd. BTIG Research upgraded Liquidia from a “neutral” rating to a “buy” rating and set a $70.00 price objective for the company in a research report on Wednesday. Lifesci Capital raised Liquidia from a “hold” rating to an “outperform” rating and set a $59.00 price objective for the company in a research note on Wednesday. Finally, Wall Street Zen lowered Liquidia from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $72.85.

Liquidia Stock Performance

NASDAQ:LQDA opened at $34.35 on Thursday. The company has a 50-day moving average of $60.09 and a 200-day moving average of $61.54. The firm has a market cap of $3.07 billion, a price-to-earnings ratio of 25.07, a price-to-earnings-growth ratio of 0.30 and a beta of 0.61. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63. Liquidia has a twelve month low of $21.94 and a twelve month high of $93.61.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The business had revenue of $171.68 million during the quarter, compared to analyst estimates of $168.48 million. During the same period in the prior year, the firm earned ($0.49) EPS. The business’s revenue for the quarter was up 1842.1% on a year-over-year basis. Analysts forecast that Liquidia will post 2.05 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Katherine Rielly-Gauvin sold 36,789 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $74.99, for a total value of $2,758,807.11. Following the completion of the sale, the director owned 44,637 shares in the company, valued at approximately $3,347,328.63. This represents a 45.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Rajeev Saggar sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $74.06, for a total transaction of $3,703,000.00. Following the completion of the transaction, the insider directly owned 142,265 shares of the company’s stock, valued at $10,536,145.90. This represents a 26.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 745,194 shares of company stock valued at $41,081,702 over the last 90 days. 25.60% of the stock is owned by corporate insiders.

Institutional Trading of Liquidia

Several large investors have recently added to or reduced their stakes in the company. Globeflex Capital L P purchased a new stake in shares of Liquidia in the second quarter valued at $175,000. Nykredit A S acquired a new stake in shares of Liquidia in the second quarter worth $177,000. Apollon Wealth Management LLC acquired a new stake in shares of Liquidia in the first quarter worth $247,000. Archer Investment Corp purchased a new position in shares of Liquidia during the first quarter valued at $259,000. Finally, Fluent Financial LLC purchased a new position in shares of Liquidia during the second quarter valued at $287,000. 64.54% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia’s settlement with United Therapeutics resolves the litigation surrounding YUTREPIA, removing a major legal overhang and improving visibility for the product’s commercialization. The stock recently rallied sharply on the news, though the agreement is described as costly. Why Liquidia Is Up After YUTREPIA Litigation Settlement
• Positive Sentiment: LifeSci Capital upgraded Liquidia to “Outperform” from “Market Perform,” reflecting increased confidence following the litigation resolution. LifeSci Capital Upgrades Liquidia
• Positive Sentiment: BTIG Research raised Liquidia to “Buy,” adding to the bullish analyst commentary. HC Wainwright also maintained a “Buy” rating and lifted its price target to $65 from $58, implying substantial upside from recent trading levels.
• Neutral Sentiment: Trading volume became unusually high after the analyst upgrades, indicating strong investor attention and repositioning following the settlement and rating changes. Liquidia Sees Unusually High Trading Volume
• Negative Sentiment: Needham & Company reduced its price target for Liquidia, signaling that some analysts believe the stock’s valuation or the financial impact of the settlement warrants a more cautious outlook. Liquidia Price Target Cut by Needham

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).